Read transcripts of debates in both Houses
Produced by Commons Library, Lords Library and Parliamentary Office Science and Technology
Search for Members by name, postcode, constituency and party
Learn about their experience, knowledge and interests
Celebrating people who have made Parliament a positive, inclusive working environment
Four staff networks for people to discuss and consider issues.
Contact your MP or a Member of the House of Lords about an issue that matters to you
Sign up for the Your Parliament newsletter to find out how you can get involved
Take a tour of Parliament and enjoy a delicious afternoon tea by the River Thames
See some of the sights you’ll encounter on a tour of Parliament
Book a school visit, classroom workshop or teacher-training session
Access videos, worksheets, lesson plans and games
Follow this EDM by:
That this House notes with serious concern that the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance for the use of the drug abiraterone, a life extending treatment for men in the final stages of prostate cancer, which could, if implemented, prevent the use of this cancer drug for the treatment of this condition in the NHS in England and Wales; is aware that prostate cancer is the most common cancer in men in the UK, that 32,500 men are diagnosed with prostate cancer and that 10,000 men die from the disease in England and Wales every year; further notes that abiraterone can extend the life of men in the final stages of prostate cancerby an average of four months and improves their quality of life; calls on the Government to act immediately to ensure that men with prostate cancer are able to access this treatment to treat their health condition and help to prolong their life; further calls on NICE to reconsider its draft guidance and recommend abiraterone for the benefit of men with prostate cancer and their families; and considers that men should be able to access this drug through the Cancer Drugs Fund, if their clinicians prescribe it, irrespective of this draft decision by NICE.
Total number of signatures: 35
Showing 35 out of 35